Unité de Recherche Clinique NeuroSciences

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis	Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome	Recruiting	Phase 2	2026-08-21		NCT06414954

Clinical trials